ELTX
Elicio Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.55
−0.64%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$1.57
From 52W high−89.56%
Volume298125.00
Market cap$41.99M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$1.57
From 52W high
−89.56%
Volume
298125.00
Market cap
$41.99M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.8x
P/E (TTM)
—
RSI (14)
21.7
MomentumView details →
1D Return
−0.64%
YTD Return
−81.22%
SummaryUpdated Jun 1, 2026
Elicio Therapeutics, Inc. (NASDAQ:ELTX) is a clinical-stage biotechnology company founded and headquartered in Boston, Massachusetts. The company went public in February 2021 and focuses on developing novel immunotherapies for cancer treatment and other diseases. As a clinical-stage biotech firm, Elicio operates without generating revenue from product sales, instead relying on research and development activities to advance its pipeline of experimental treatments through various phases of clinical trials.
Similar companies
Latest newsMore news →
Elicio Therapeutics announced that new pre-specified analyses from the randomized Phase 2 AMPLIFY-7P study of ELI-002 7P (camupepimut) in resected pancreatic ductal adenocarcinoma were selected for a late-breaking Proffered Paper oral presentation at the ESMO Congress 2026 in Madrid, Spain.25d agoElicio Therapeutics priced a registered direct offering of 4,380,313 shares of common stock for gross proceeds of approximately $15 million.110d agoElicio Therapeutics reported clinical observations for its ELI-002 7P cancer drug, indicating durable responses.124d ago